Compare Enveric Biosciences Inc (ENVB) vs SYSCO Corporation (SYY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs SYSCO Corporation — how do they compare? Enveric Biosciences Inc trades at $1.39 (market cap $5.32M), while SYSCO Corporation trades at $82.63 (market cap $38.60B). The key difference: SYSCO Corporation is far larger — about 7255.6× Enveric Biosciences Inc's market cap, and SYSCO Corporation pays a 2.73% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| ENVB | SYY | |
|---|---|---|
Market Cap | $5.32M | $38.60B |
Sector | Health | Consumer Staples |
52-Week High | $17.40 | $91.16 |
52-Week Low | $1.28 | $69.30 |
Enterprise Value | $408.82K | $52.08B |
Dividend Yield | — | 2.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.41, up 6.82% in the last session. The stock shows a bearish technical trend with moving averages signaling sell, but oscillators are neutral. Financially, the company reported a net loss of $8.77M for 2025, with negative ROE and ROA, though it consistently beat EPS expectations. Recent news highlights participation in investor conferences and progress with its neuroplastogen candidate EB-003.
Outlook is speculative with high risk due to negative profitability and cash burn, offset by strong analyst buy ratings (75%) and positive clinical updates. Key risks include funding needs and drug development hurdles, while catalysts hinge on regulatory milestones and partnership news.
Sysco Corporation (SYY) trades at $82.85, down 0.73% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $83.67. The company reported mixed recent earnings, missing estimates in Q1 2026 but beating in the prior two quarters. Revenue growth has been steady, reaching $81.37B in 2025, though net income margin has softened to 2.08%. Recent news highlights operational planning for the 2026 FIFA World Cup and recognition for AI innovation in its supply chain.
The outlook is cautiously positive, supported by analyst consensus and stable cash flow generation. Key opportunities include continued market share gains in food distribution and efficiency initiatives. Primary risks involve margin pressure from inflation, high leverage with a debt-to-asset ratio near 50%, and exposure to cyclical foodservice demand, which could impact earnings growth and shareholder returns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About SYSCO Corporation
Sysco is the largest U.S. food-service distributor, boasting 17% market share of the highly fragmented food-service distribution industry. Sysco distributes over 400,000 food and nonfood products to restaurants (63% of revenue), healthcare facilities (8%), education and government buildings (8%), travel and leisure (7%), and other locations (14%) where individuals consume away-from-home meals. In fiscal 2022, 82% of the firm's revenue was U.S.-based, with 7% from Canada, 4% from the U.K., 2% from France, and 4% other.
Read more on SYY →
